Click on image to view larger version.

Figure 1 Stratified analyses of aggregate 30-day costs by treatment group according to prespecified patient characteristics. The graph indicates the mean difference in costs between the bivalirudin + provisional glycoprotein (GP) IIb/IIIa and heparin + routine GP IIb/IIIa groups (black squares) along with the associated 95% confidence interval (bars). There was no evidence of heterogeneity of treatment effect across any of the subgroups (p value for interaction >0.05).